Research programme: protein targeted therapeutics - Jiangsu Hansoh Pharmaceuticals
Latest Information Update: 28 Oct 2023
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Anti-infectives; Antihyperglycaemics; Antineoplastics; Cardiovascular therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; CNS disorders; Diabetes mellitus; Gastrointestinal disorders; Infections
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for research development in Cancer in China
- 28 Oct 2023 No recent reports of development identified for research development in Cancer in USA
- 28 Oct 2023 No recent reports of development identified for research development in Cardiovascular-disorders in China